33 C
Vientiane
Wednesday, May 21, 2025
spot_img
Home Blog Page 620

China Auto Valley • Wuhan-made Auto Brands Gather at Global Launch Event

WUHAN, China, Feb. 24, 2025 /PRNewswire/ — A report from Changjiang Daily.

VOYAH Ultra-Fast Charging Station Tops Global Speed Rankings

On February 23, the Chinese Auto Valley • Press Conference on the Global Launch of Wuhan-Made Auto Brands was held at Dongfeng Motor Global Innovation Center. Brands including Voyah, Dongfeng Honda, Dongfeng M-Hero, Lotus Cars, Dongfeng eπ, Dongfeng Aeolus, and Dongfeng Nammi formed a brand cluster to make their first collective appearance to showcase the innovation capabilities of Wuhan-made vehicles in the era of automotive intelligence.

Dongfeng Motor Global Innovation Center
Dongfeng Motor Global Innovation Center

Auto Valley to launch 1 to 2 new models quarterly over next three years

At the press conference, leader of the Wuhan Economic & Technological Development Zone announced that China’s Auto Valley has established a comprehensive vehicle matrix spanning mainstream, premium, and luxury segments. Over the next three years, the region will release 1 to 2 new models per quarter, including PHEV, EREV, BEV, and hydrogen-powered vehicles, covering price ranges from 50,000 yuan to 1 million yuan

Voyah will “go all-in on intelligent technology” in 2024, becoming China’s first automaker to equip its full lineup (SUVs, MPVs, sedans) with Huawei’s Qiankun intelligent driving system and Harmony cockpit operating system, aiming to hit its annual sales target of 200,000 units. To address range anxiety, Voyah has developed the world’s first megawatt-level ultra-fast charging station, “Voyah VP1000,” achieving a 1.7 km range per second of charging (15-minute charge for 515 km range)—the world’s fastest charging speed. 

The Dongfeng Honda S7, Wuhan’s first locally built premium electric SUV, will make its fully electric debut in early March 2024.

By late February, Lotus will roll out urban NOA (Navigation on Autopilot) in 16 Chinese cities, solidifying its status as the only million-RMB luxury sports brand globally to implement mapless NOA technology.

In H1 2025, Dongfeng M-Hero will launch the M-Hero 917 Extended Edition (high-end customization), while in H2 2025, a new intelligent electric off-roader co-developed with Huawei’s full-stack tech will debut. Previously, M-Hero has collaborated with luxury brand Lorinser to create a M-Hero M800 Stellar Armored Vehicle. It has also collaborated with the movie Operation Leviathan to debut China’s first movie co-branded vehicle M-Hero 917 Dragon Armor Edition. These models have built M-Hero’s current lineup spanning from 600,000 to 1,000,000 yuan.

Dongfeng has unified management of three brands: Dongfeng Aeolus, Dongfeng eπ, and Dongfeng Nammi. Over the next three years, they will launch 30 new models, including Nammi 06. There will also be upcoming debut of 2025 refreshes of eπ007 and eπ008, as well as a new Aeolus PHEV.

Voyah to achieve near-full coverage in European markets by next year

This year, Dongfeng’s brands are fully committed to expanding their global presence.

Voyah has consistently pursued a “premium globalization strategy”. Li Boxiao, Deputy General Manager of Voyah’s Sales and Service Company, revealed that by 2026, Voyah will achieve near-complete coverage across European countries, complete strategic deployments in Central Asia, the Middle East, as well as Central and South America. It will also enter right-hand drive markets. “By 2030, cumulative overseas sales will exceed 500,000 units,” he stated.

Rooted in Wuhan, Dongfeng M-Hero is expanding nationwide and globally. Tao Haiying, Brand Operations Director of Dongfeng M-Hero Technology, highlighted that the brand has successfully entered high-end markets such as Switzerland, the UAE, and Qatar, offering “custom-tailored” products and services for global consumers.

2025 marks Lotus’ ‘Year of Brand’,” said Qiao Xinyu, Vice President of the brand’s marketing section. The automaker will leverage iconic milestones including the 40th anniversary of Ayrton Senna’s championship, the 50th anniversary of the Esprit model, and the 75th anniversary of Lotus’ first F1 victory, to amplify its brand appeal.

This year, Wuhan Economic & Technological Development Zone will kick off the “Auto Valley Made • Global Journey,” a 2025 automotive roadshow series to boost consumption. Featuring three themes Jingchu Tour, China Tour, and Global Tour, the campaign will host 18 tour events. Auto brands under Dongfeng, including Voyah, M-Hero, eπ, and Honda, will embark from Wuhan on tours nationwide and worldwide.

Double subsidies for Dongfeng vehicle purchases in 2025

During the event, it was announced that an auto purchase voucher program will continue to be issued this year, with subsidies doubled for consumers.

From January 1 to December 31, 2025, consumers purchasing eligible models, including both new energy vehicles (NEVs) and fuel-powered vehicles, under the brands VOYAH, Dongfeng M-Hero, Dongfeng eπ, Dongfeng Aeolus, Dongfeng Honda, and Lotus, within Hubei Province will enjoy doubled subsidies, namely the tiered incentives increase from 2024’s original amounts of 1,000/2,000/4,000 yuan to 2,000/4,000/6,000 yuan. Additionally, auto purchase vouchers can be stacked with national, provincial, and municipal consumption-boosting policies for maximum benefits.

 

LabConnect and Australian Clinical Labs’ Specialised Trials Announce Strategic Partnership in Australia and Asia Pacific Region

PORT MELBOURNE, Australia and JOHNSON CITY, Tenn., Feb. 24, 2025 /PRNewswire/ — LabConnect and Australian Clinical Labs’ (ACL) Specialised Trials have forged a strategic partnership to expand support of clinical trials in Australia and the Asia-Pacific region.

This exclusive, multi-year agreement solidifies the partnership, and enables both organizations to leverage complementary strengths to help get patients the medicines they need by meeting the growing regional demand of clinical trial support services for pharmaceutical, biotechnology, and clinical research organizations.

ACL Specialised Trials is one of the leading clinical trials laboratories in Australia, managing large biotech and pharmaceutical clinical trials from Phase 1 to Phase 4 studies. With a vast network of laboratories across Australia, ACL Specialised Trials has extensive experience in delivering end to end pathology solutions and a wide range of clinical trials central laboratory services for national, multi-site and single site clinical trial studies. 

“This long-term partnership will help global clients access Australian patients and bring key international trials to this part of the world – ultimately resulting in the advancement of leading-edge medical breakthroughs that can save lives and improve patient outcomes,” stated ACL Group Executive CEO, Melinda McGrath. “It will strengthen our position as a key player in a growing $8 billion market and I am excited to showcase our depth of experience and talented team on the world stage. This is fantastic news for our communities, and we are proud to be partnering with LabConnect.”

As the world’s most agile central laboratory solutions partner, LabConnect will leverage ACL’s extensive test menu with a comprehensive range of services to support the region including in-country lab kit building, biospecimen management, project and data management, and logistics support. Catherine Osborne, APAC General Manager, leads LabConnect’s growing operations and business in the region.

As LabConnect’s primary laboratory services provider for Australia and the broader APAC region, ACL Specialised Trials will support LabConnect with their dedicated, clinical trials laboratory and project team situated in Port Melbourne, Victoria, serving as the operational hub for the region. 

Wes Wheeler, LabConnect CEO, added, “Our clients increasingly include Asian Pacific investigative sites in their clinical development plans and our partnership with ACL Specialised Trials provides us with a platform from which we can deliver our comprehensive suite of industry-leading central laboratory services across the region.”

About ACL Specialised Trials

Specialised Trials is a subsidiary of Australian Clinical Labs, showcasing our commitment to improving patient lives through medical excellence, market-leading technology and a talented team of experts. ACL Specialised Trials offers a dedicated pathology approach to Phase I-IV clinical trials, delivering quality solutions for our clients. Our state-of-the-art, purpose-built facility and years of experience with commercial and clinical trials ensures a seamless transition from initial inquiry through to delivery.

Visit us at specialisedtrials.com.au
Follow us on LinkedIn

About LabConnect

LabConnect is the world’s most agile central laboratory solutions partner, providing technology-driven, customized, orchestrated, and scalable support services for clinical trials of all sizes and complexity. With over 20 years experience and 1,900+ clinical studies across 93 countries, LabConnect is the trusted partner for biotechnology, pharmaceutical, and clinical research organizations.

With modern operations and strategic alliances with world-leading laboratories, LabConnect is uniquely positioned to provide access to the latest innovation and automation. LabConnect delivers exceptional service with a comprehensive suite of central laboratory solutions including custom lab kits, advanced sample tracking and integrated logistics, global standardized sample processing, industry-leading testing menu of 10,200+ validated assays, worldwide support for radiopharmaceuticals, and next-generation biorepository.

LabConnect scientific experts support pre-clinical and clinical studies with scientific project management, bioanalytical and biospecimen management, biomarker strategy and logistics solutions. LabConnect excels at data management, integrating complex datasets from diverse sources into a single, cohesive, submission-ready dataset.

Follow LabConnect on LinkedIn
Learn more at labconnect.com

Photo – https://laotiantimes.com/wp-content/uploads/2025/02/labconnect_and_australian_clinical_labs_specialised_trials_partnership.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/02/labconnect_logo-1.jpg

Risen Storage to Showcase New Flexible Energy Storage System “eFlex” at Japan’s “World Smart Energy Week 2025”

TOKYO, Feb. 24, 2025 /PRNewswire/ — Risen Storage was excited to unveil its latest flexible product “eFlex” at World Smart Energy Week 2025 in Tokyo on February 19, 2025. This advanced system is a flexible solution with an 836 kWh minimum building block and can be configured to a system with up to 6.7MWh capacity which designed for international markets, specifically targeting Europe, North America, and Japan, offering enhanced performance, flexibility, and adaptability to meet the diverse energy needs of these regions.


Maximizing Energy Density and Space Utilization:
The newly launched “eFlex” energy storage system delivers efficient performance with its compact design, maximizing land use. Its high energy density and liquid cooling technology ensure optimal performance and minimal space requirements, making it ideal for areas with limited land.

Convenient Transportation and Installation:
Designed for regions with challenging infrastructure like rural Europe, Africa, North America, the Caribbean, and Japan, the system ensures smooth delivery across various terrains. Its modular and liquid-cooled design enables flexible installation, reducing time and costs, suitable for both urban and rural settings.

Exceptional Adaptability:
The liquid-cooled system operates efficiently from -40°C to 55°C, ensuring reliable performance in diverse climates across Europe, North America, and Japan. With strong seismic resistance and IP55 protection, it is built to withstand harsh environments, offering long-term stability.

Flexibility and Modularity:
The system supports parallel connections of 6-8 units, offering customizable capacities from 836kWh to 6.7MWh per system. Its modular design reduces energy consumption and boosts overall system efficiency.

Comprehensive Certifications and High Safety Standards:
The system meets international certifications such as UL9540, UL9540A, CE, and NFPA 68/69, ensuring top safety standards. Equipped with MSD fuses, explosion-proof valves, and intelligent BMUs, it guarantees long-term reliability and safety, backed by Risen Storage’s commitment to quality.

About Risen Storage
Risen Storage has 19 years of experience in lithium battery solutions, specializing in PCS, BMS, EMS, C&I, and large-scale BESS. Its Energy Storage Battery System is the first in China to pass UL9540A certification in both the US and China. With a production capacity over 15 GWh, Risen Storage has deployed large-scale projects globally, delivering over 100 MW and earning worldwide recognition for quality and service.

Visionary Holdings Navigates a New Era of Precision Medicine, Achieving Major Breakthroughs in Targeted Therapy

TORONTO, Feb. 24, 2025 /PRNewswire/ — In today’s era of rapid technological advancement, the deep integration of artificial intelligence and the medical field is bringing unprecedented hope to human health. Among these advancements, targeted therapy, a cornerstone of precision medicine, is gradually reshaping the treatment landscape for cancer and other major diseases with its unique advantages. Visionary Holdings (Nasdaq Stock Code: GV), a globally influential multinational corporation, stands at the forefront of this medical revolution, leading targeted therapy to new heights.

Targeted therapy, an innovative treatment based on molecular biology, precisely targets diseased cells while sparing healthy ones, significantly improving treatment efficacy and reducing the side effects associated with traditional radiotherapy and chemotherapy. Drugs like Erlotinib for EGFR-mutated non-small cell lung cancer and Herceptin for HER2-positive breast cancer have markedly improved patient survival rates. With the progress of precision medicine, targeted therapy is not only excelling in cancer treatment but is also expanding into areas such as neurodegenerative diseases and autoimmune disorders. According to McKinsey Global Institute, the global biopharmaceutical market is projected to exceed $1.5 trillion by 2030, with the precision medicine sector expected to grow at a compound annual growth rate (CAGR) of over 10%, indicating a highly promising future for targeted therapy.

Visionary Holdings has keenly recognized the immense potential of the biopharmaceutical field and has actively invested in cutting-edge areas such as tumor-targeted therapy, gene sequencing, AI-assisted drug development, and liquid biopsy. The company is focused on advancing next-generation immunotherapies, gene editing, and precision oncology, enhancing biomarker detection and liquid biopsy technologies, and leveraging AI to accelerate drug development. It has also successfully developed rapid at-home testing technologies for cervical and colorectal cancers, increasing cancer screening coverage and providing significant convenience for early diagnosis.

In practical terms, Visionary Holdings has driven substantial breakthroughs in targeted therapy through a series of strategic investments and collaborations. The company has made strategic investments in leading biotech firms to co-develop third-generation EGFR inhibitors aimed at overcoming drug resistance in non-small cell lung cancer patients. This drug is currently in global clinical trials and has garnered widespread attention. Additionally, Visionary Holdings has partnered with top gene sequencing companies to develop liquid biopsy technologies, enabling real-time monitoring of cancer progression through non-invasive blood tests, making treatments more precise and efficient.

Furthermore, Visionary Holdings has collaborated with numerous global biotech leaders, AI pharmaceutical giants, and medical research institutions to pioneer innovative projects. In targeted drug development, the company is focusing on specific gene mutations such as HER2, BRAF, and KRAS to develop next-generation anticancer drugs. By utilizing AI drug discovery technologies, deep learning algorithms are employed to analyze protein structures, significantly speeding up drug screening and optimization. Its global clinical trial network spans North America, Europe, and Asia, accelerating the time-to-market for new drugs and benefiting more patients.

Looking ahead, the combination of targeted therapy and immunotherapy will become a trend, and AI will be deeply integrated into precision medicine, substantially shortening drug development cycles and reducing costs. The application scope of targeted therapy will continue to expand, offering hope to patients with a wider range of diseases. Visionary Holdings will continue to leverage its cutting-edge technology, strategic vision, and global collaboration network to deepen its commitment to targeted therapy and precision medicine. The company is dedicated to developing next-generation targeted drugs, improving global patient access to advanced treatments, leading the new era of precision medicine, and writing a new chapter in the pursuit of human health.

For more information, please contact:

Visionary Holdings Inc.
Investor Relations Department
Email: ir@farvision.ca 

Air Premia Enhances Flight Safety with IATA Turbulence Aware

  • Air Premia to Adopt IATA Turbulence Aware Starting March 1, 2025
  • Real-Time Turbulence Data to Enhance Safety and Passenger Comfort

SEOUL, South Korea, Feb. 24, 2025 /PRNewswire/ — Air Premia (CEO Kim Jae-hyun, Yoo Myung-sub) announced today that it will introduce IATA Turbulence Aware, a cutting-edge safety tool developed by the International Air Transport Association (IATA), starting on March 1, 2025. This advanced system leverages real-time in-situ turbulence reports to enhance flight safety and passenger comfort. As of the end of last year, more than 25 airlines worldwide were contributing and utilizing Turbulence Aware data across more than 2,600 aircraft. By accessing real-time turbulence information, Air Premia’s flight crews will be better equipped to avoid or mitigate the effects of turbulence, ensuring safer and smoother flights.

According to the Ministry of Land, Infrastructure, and Transport, airlines experienced 14,802 turbulence encounters in the first half of 2024, marking a 78% increase compared to five years ago. By adopting Turbulence Aware, Air Premia can shift from a forecast-based response to a real-time response, thereby improving its ability to secure safer flight paths.

The implementation of Turbulence Aware will enable Air Premia to effectively respond to Clear Air Turbulence (CAT) in airspace where turbulence was not predicted, and to adjust flight operations when predicted turbulence does not occur, reducing safety incidents for both passengers and crew.

In addition to joining the platform, Air Premia is committed to safety by sharing turbulence information in pre-flight briefings with flight and cabin crew, adjusting service timings for passengers, and introducing GE Aerospace’s flight data monitoring system, ‘Safety Insight,’ to identify and manage potential risks during flights.

Koh Yoon Beom, Director of Safety & Security Division at Air Premia, stated, “By adopting IATA Turbulence Aware, we can strengthen customer trust and enhance our safety image. We are dedicated to providing a safe and comfortable flying experience for our passengers.”

Dr. Xie Xingquan, IATA’s Regional Vice President for North Asia and Asia Pacific (ad interim) said: “We welcome the participation of Air Premia in Turbulence Aware. Making use of accurate and up-to-date data in Turbulence Aware helps flight crews’ efforts to avoid or at least mitigate the effects of turbulence. The quality of this data improves with each new contributing airline. Air Premia’s contribution will help the industry improve the safety and comfort of crew and passengers alike.”

About Air Premia
Air Premia is Korea’s only Hybrid Service Carrier (HSC), offering high-quality services at reasonable prices based on its unique philosophy of providing essential premium services.

YEEDI S14 PLUS: Unleashing the Future of Clean with Innovative OZMO Roller Mopping Technology

SAN FRANCISCO, Feb. 24, 2025 /PRNewswire/ — Leading robot vacuum brand YEEDI today announced the launch of its latest flagship robot vacuum, YEEDI S14 PLUS. The YEEDI S14 PLUS sets an entirely new standard for home cleaning, combining stunning design with revolutionary performance. Powered by the cutting-edge OZMO Roller Instant Self-Washing Mopping Technology, developed in collaboration with Tineco—a global leader in floor cleaning innovation. In celebration of the launch, YEEDI is offering an exclusive discount for a limited time.

YEEDI S14 PLUS
YEEDI S14 PLUS

Step into a New Era of Cleaning with Roller Mopping Technology

Traditional floor cleaning methods, such as flat-pad mopping and dual-plate systems, have long been the go-to solutions—but they come with their share of drawbacks. Flat-pad mops often struggle with tough stains, while dual-plate systems, though more powerful, tend to leave streaks after cleaning and create heavy water residue, leaving floors wet and messy for long periods.

The YEEDI S14 PLUS redefines the floor cleaning experience with its groundbreaking OZMO Roller instant self-washing mopping system, ushering in a new era of floor care. Unlike traditional flat-pad mops, which often fail to tackle stubborn stains, or dual-plate systems that leave streaks and excess moisture, the OZMO Roller addresses these pain points head-on. It offers real-time self-cleaning, ensuring the mop remains fresh and effective throughout the entire process—leaving no residue and allowing for faster drying times. This revolutionary Roller Mopping Technology redefines floor care, providing powerful, precise, and hassle-free cleaning. The future of spotless floors is here, rolled into one perfect package with the YEEDI S14 PLUS.

Revolutionary Floor Cleaning Technology

The YEEDI S14 PLUS revolutionizes home cleaning with the OZMO Roller instant self-washing mopping system. This high-speed, ultra-high-pressure cleaning technology spins at 200 RPM, exerting 4000 Pa of downward pressure to tackle stubborn stains without leaving residue or streaks. Featuring real-time mop washing with 16 nozzles delivering clean water up to 200 times per minute, it ensures the mop stays clean throughout the process, maximizing cleaning efficiency.

Powerful Performance and Smart Navigation

With 18,000Pa ‘Hurricane’ suction, the YEEDI S14 PLUS effortlessly picks up dirt, dust, and debris from all surfaces, including thick carpets. The TrueEdge 2.0 adaptive edge cleaning and advanced 3D edge sensing work together to ensure precise coverage along edges and corners. Additionally, the AIVI 3D 3.0 Omni-Approach technology enables real-time mapping and intelligent navigation, allowing the vacuum to avoid obstacles and optimize cleaning paths.

Pet-Friendly and Hassle-Free Maintenance

Say goodbye to tangled hair with the ZeroTangle 2.0 technology, designed specifically to make cleaning easy in homes with pets. The YEEDI S14 PLUS also includes a self-emptying station with a 3.4L dust bag, hot water mop washing (167°F), and hot air drying (145°F), ensuring your mop stays fresh. With up to 270 minutes of cleaning on a single charge, it’s built to handle larger spaces with ease.

Intelligent Control and Customization

Control your cleaning experience effortlessly through the YEEDI companion app, or via voice assistants such as Alexa, Siri, and Google Assistant. Additional features like suction boost, mop-lifting, and smart multi-pass cleaning give you complete control, while customizable cleaning schedules tailor the vacuum’s performance to your specific needs.

Award-Winning Innovation at CES 2025

The YEEDI S14 PLUS has taken the spotlight at CES 2025, earning the prestigious Indoor Cleaning Technology Innovation Gold Award from Global Top Brands. This recognition solidifies YEEDI’s leadership in pushing the boundaries of robotic vacuum technology, showcasing the brand’s commitment to redefining the future of home cleaning with cutting-edge, game-changing innovations.

Pricing and Availability

Get the YEEDI S14 PLUS today for MSRP $1,399, and save $450 with our exclusive launch promotion—bringing the price down to just $949. Don’t miss your chance to experience the future of home cleaning at an unbeatable price!

More at

Amazon Store:  https://www.amazon.com/yeedi

YEEDI S14 PLUS:  https://www.amazon.com/dp/B0DRNYXDDV

About YEEDI

YEEDI is a cutting-edge service robot brand that embraces the concept of “Live Smart. Enjoy Life.” With constant upgrades, pioneering technology solutions are integrated into robotics for an enhanced consumer experience. Thus, consumers can enjoy a modern lifestyle with high standards of quality.

ZK International Group Co., Ltd. Resolves Nasdaq Bid Price Deficiency and Remains in Compliance with Nasdaq Listing Standards

WENZHOU, China, Feb. 24, 2025 /PRNewswire/ — ZK International Group Co., Ltd. (Nasdaq: ZKIN) (“ZK International” or the “Company”), a leading engineering Company focused on high-performance steel products, is pleased to announce that the bid price deficiency concern raised by Nasdaq has been successfully resolved.

The Company has received written notification (the “Nasdaq Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the “Listing Rules”).

The Nasdaq Notice confirms that the Company has regained compliance with Listing Rule 5550(a)(2), as the Company’s closing bid price exceeded US$1.00 for 10 consecutive business days. On February 14, 2025, the Staff notified the Company that it has regained compliance with the Rule and the matter is now closed.

ZK International Group Co., Ltd. remains committed to maintaining the highest standards of corporate governance and compliance. The company appreciates the support of its shareholders and looks forward to continuing to deliver value through its innovative products and services.

For more information please visit www.ZKInternationalGroup.com. Additionally, please follow the Company on TwitterFacebookYouTube, and Weibo. For further information on the Company’s SEC filings please visit www.sec.gov.

About ZK International Group Co., Ltd.:

ZK International Group Co., Ltd. is a China-based engineering company building and investing in innovative technologies for the modern world. With a focus on designing and implementing next-generation solutions through industrial, environmental and software engineering, ZKIN owns 28 patents, 21 trademarks, 2 Technical Achievement Awards, and 10 National and Industry Standard Awards.  

ZKIN’s core business is to engineer and manufacture patented high-performance stainless steel and carbon steel pipe products that effectively deliver high quality, highly-sustainable and environmentally sound drinkable water to the Chinese, Asia and European markets.  ZK International is Quality Management System Certified (ISO9001), Environmental Management System Certified (ISO1401), and a National Industrial Stainless Steel Production Licensee.  It has supplied stainless steel pipelines for over 2,000 projects, which include the Beijing National Airport, the “Water Cube” and “Bird’s Nest”, which were venues for the 2008 Beijing Olympics.  ZK International is preparing to capitalize on the $850 Billion commitment made by the Chinese Government to improve the quality of water, which has been stated to be 70% unfit for human contact.  

Safe Harbor Statement 

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict and many of which are beyond the control of ZK International.  Actual results may differ from those projected in the forward-looking statements due to risks and uncertainties, as well as other risk factors that are included in the Company’s filings with the U.S. Securities and Exchange Commission. Although ZK International believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized.  In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by ZK International or any other person that their objectives or plans will be achieved. ZK International does not undertake any obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

 

ALL INDIVIDUALS WHO PURCHASED OR ACQUIRED IMPACT THEORY FOUNDER’S KEYS BETWEEN OCTOBER 13, 2021, AND DECEMBER 6, 2021

COSTA MESA, Calif., Feb. 24, 2025 /PRNewswire/ — The following statement is being issued by Simpluris, Inc., Fund Administrator for the United States Securities and Exchange Commission, regarding the Impact Theory Fair Fund and Plan of Distribution.

NOTICE OF FAIR FUND DISTRIBUTION PLAN
In the Matter of Impact Theory, Inc.
Administrative Proceeding File No. 3-21585

For more information, visit www.ImpactTheoryFairFund.com

The United States Securities and Exchange Commission (“SEC”) has settled administrative proceedings (the “Order”) against Impact Theory (the “Respondent”). In the Order, the SEC found that from October 13, 2021, to December 6, 2021, Impact Theory violated Sections 5(a) and 5(c) of the Securities Act by offering and selling crypto asset securities known as Founder’s Keys without having a registered statement filed or in effect with the SEC or qualifying for an exemption from registration.

The SEC ordered the Respondent to pay $5,120,718.27 in disgorgement, $483,195.90 in prejudgment interest, and a $500,000.00 civil money penalty, for a total of $6,103,914.17, to the SEC. The SEC also created a Fair Fund, pursuant to Section 308(a) of the Sarbanes-Oxley Act of 2002, so the penalty collected, along with the disgorgement and interest collected, could be distributed to harmed investors (the “Fair Fund”).

The Fair Fund will be paid out according to the Plan of Distribution (“Plan”).

A summary of the eligibility criteria and claims process is below. Full details are available at www.ImpactTheoryFairFund.com. You may also request a copy of the Plan from the Fund Administrator via email at info@ImpactTheoryFairFund.com or by calling 833-285-3401.

Who is eligible to receive a payment from the Fair Fund? To receive a payment, you must have:

  1. purchased or acquired Founder’s Keys between October 13, 2021, and December 6, 2021;
  2. submitted a timely Claim Form;
  3. suffered a Recognized Loss as calculated under the Plan; and
  4. not been an Excluded Party under the Plan.

How do I submit a Claim? The easiest way to submit a claim is online at the Impact Theory Fair Fund website: www.ImpactTheoryFairFund.com. Claim Forms completed online must be submitted on or before 11:59 p.m. Eastern Standard Time on August 15, 2025.

If you are unable to submit a Claim Form online and/or you have lost relevant credentials associated with wallets and/or exchanges required as part of an online claim, you may request a copy of the paper Claim Form from the Fund Administrator via email at info@ImpactTheoryFairFund.com or by calling 833-285-3401. You may also download a copy of the Claim Form to print at: www.ImpactTheoryFairFund.com. Claim Forms submitted via mail must be sent to the address provided on the Claim Form and postmarked (or if not sent by U.S. Mail, then received) by August 15, 2025.

The Fund Administrator will send a Determination Notice advising each claimant who timely submitted a Claim Form of their eligibility determination and will provide a calculation of Recognized Loss to those determined to be Eligible Claimants. The Fund Administrator may consider disputes of an Eligible Claimant’s Recognized Loss calculation if timely submitted in accordance with the Plan.

This notice is a summary. For more information, visit
www.ImpactTheoryFairFund.com